About

About CyGenica Limited CyGenica is a pioneering biotech startup redefining the intracellular delivery of genomic medicines through its proprietary platform, GEENIE — an engineered protein nanoneedle capable of delivering payloads directly into the cytoplasm, bypassing endocytosis. GEENIE enables safe, efficient, and targeted delivery of a broad range of therapeutic modalities including siRNA, ASOs, CRISPR-Cas, and gene therapy vectors, addressing one of the most critical bottlenecks in the field of genetic medicine. Our mission is to empower next-generation therapies with precision delivery tools that overcome biological barriers, reduce off-target effects, and improve therapeutic outcomes — especially in tissues traditionally considered hard to reach such as the brain and eye. CyGenica has secured strategic collaborations with two top-tier global pharma/biotech partners. In one collaboration, we demonstrated that GEENIE enabled a clinically validated RNAi candidate to achieve equivalent gene knockdown efficacy at 100-fold lower doses — a breakthrough with substantial implications for safety, dosing, and cost. Our initial in vivo proof-of-concept (POC) studies demonstrated tissue-specific targeting using GEENIE conjugated to a cytotoxic payload (Maytansine) in glioblastoma models, as well as HER2-gastric cancer tumor xenografts. While these programs validated the platform’s targeting and delivery capabilities, we have strategically pivoted toward higher-value opportunities in CNS and ocular indications, where GEENIE’s unique delivery mechanism offers clear differentiation and unmet need. CyGenica holds four granted patents (2 in the U.S., 1 in Europe, and 1 in Japan), protecting the core GEENIE technology. As we scale our partnerships and pipeline, we are actively seeking collaborators across therapeutic areas to co-develop or license delivery-enabled programs powered by GEENIE.